Section Arrow
Quote
NAMS.NASDAQ
- NewAmsterdam Pharma Company NV
Quotes are at least 15-min delayed:2026/04/21 21:21 EDT
Regular Hours
Last
 32.48
-1.34 (-3.96%)
Day High 
34.175 
Prev. Close
33.82 
1-M High
36.73 
Volume 
942.45K 
Bid
28
Ask
35.21
Day Low
32.29 
Open
33.7 
1-M Low
28.81 
Market Cap 
3.89B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 34.42 
20-SMA 32.89 
50-SMA 32.79 
52-W High 42 
52-W Low 16.785 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.72/0.47
Enterprise Value
3.89B
Balance Sheet
Book Value Per Share
5.94
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
22.50M
Operating Revenue Per Share
0.13
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
ASBPAspire Biopharma Holdings Inc.0.1968-0.0651-24.86%-- 
XRTXXORTX Therapeutics Inc.2.69+0.44+19.56%-- 
TOVXTheriva Biologics Inc0.3387-0.0713-17.39%0.09PE
GERNGeron Corp1.5-0.06-3.85%-- 
SPRCSciSparc Ltd.5.99+1.76+41.61%0PE
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.